Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor Therapy for RefrACTORy Migraine Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least one year history of Episodic or Chronic migraine headache symptoms~* At least 6 headache days per month~* Subject able to complete online daily headache log~Exclusion Criteria:~* Inability to understand the study or history of non-compliance with medical advice~* Currently taking a P2Y12 inhibitor~* Known hypersensitivity to Brilinta/ticagrelor~* History of stroke/transient ischemic attack (TIA) in the previous 6 months~* Active bleeding from any site~* Active peptic ulcer disease or upper gastrointestinal (GI) bleeding within six (6) months~* Migraine onset after 50 years of age~* Renal impairment: Creatinine Clearance \< 60 cc/min~* Severe hepatic impairment with total bilirubin \> 3.0 mg/dL~* Thrombocytopenia with platelet count \< 100,000 / ul~* History of intracranial hemorrhage~* Contraindications to blood thinner therapy or history of major bleeding episode while taking blood thinner therapy~* Need for chronic oral anti-coagulation therapy (i.e. Atrial Fibrillation)~* Need for chronic anti-platelet therapy (i.e. drug-eluting (DE) Stent), including daily aspirin use~* Need for daily nonsteroidal anti-inflammatory drug (NSAID) use~* Need for daily carbamazepine therapy or other strong CYP3A inhibitors or potent CYP3A inducers~* Need for simvastatin or lovastatin greater than 40 mg daily~* Symptomatic bradycardia or syncope~* Pregnancy or currently breast-feeding, or plan to become pregnant during the study period~* Planned surgery during the study time-frame~* Previously implanted patent foramen ovale (PFO), atrial septal defect (ASD), pacemaker, inferior vena cava filter, or left atrial appendage closure device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 90 mg twice per day (Type: EXPERIMENTAL): Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).